Tarsus Pharmaceuticals price target raised to $85 from $80 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $85 from $80 and keeps a Buy rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.